Faculty profile
Anton Neschadim
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Engineered Thymidine-Active Deoxycytidine Kinase for Bystander Killing of Malignant Cells.
Methods in molecular biology (Clifton, N.J.) · 2019 · first author
Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns.
Journal of immunotherapy (Hagerstown, Md. : 1997) · 2016
Extracellular histones identified in crocodile blood inhibit in-vitro HIV-1 infection.
AIDS (London, England) · 2016
Latest funding
- $60,000
CIHR Science to Business Program
CIHR · 2014 · Nominated PI
20 publications.
Engineered Thymidine-Active Deoxycytidine Kinase for Bystander Killing of Malignant Cells.
Neschadim A, Medin JA
Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns.
Resetca D, Neschadim A, Medin JA
Extracellular histones identified in crocodile blood inhibit in-vitro HIV-1 infection.
Kozlowski HN, Lai ET, Havugimana PC, White C, Emili A, Sakac D, Binnington B, Neschadim A, McCarthy SD, Branch DR
Small molecule phagocytosis inhibitors for immune cytopenias.
Neschadim A, Kotra LP, Branch DR
Mouse Models for Immune-Mediated Platelet Destruction or Immune Thrombocytopenia (ITP).
Neschadim A, Branch DR
c-SRC protein tyrosine kinase regulates early HIV-1 infection post-entry.
McCarthy SD, Sakac D, Neschadim A, Branch DR
Targeting the relaxin hormonal pathway in prostate cancer.
Neschadim A, Summerlee AJ, Silvertown JD
Mouse models of autoimmune diseases: immune thrombocytopenia.
Neschadim A, Branch DR
Cytokine profiles in mouse models of experimental immune thrombocytopenia reveal a lack of inflammation and differences in response to intravenous immunoglobulin depending on the mouse strain.
Leontyev D, Neschadim A, Branch DR
Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts.
Neschadim A, Pritzker LB, Pritzker KP, Branch DR, Summerlee AJ, Trachtenberg J, Silvertown JD
CIHR Science to Business Program
Principal investigators: Neschadim, Anton
Keywords: 'Suicide' Gene Therapy Of Cancer; Bone Marrow Transplantation; Cancer Therapy; Cancers Of The Endocrine System; Gene Therapy; Gene Therapy Of Rare Diseases; Graft-Versus-Host Disease; Immunology; Prostate Cancer; Regenerative Medicine
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Business Administration
- Banting and Best Department of Medical Research
- Mechanical Engineering
- Laboratory Medicine & Pathobiology
Co-authors at University of Toronto, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.